Quantum Genomics (ALQGC.PA) Osake Kurssi
Quantum Genomics Kurssi
Quantum Genomicsn liikevaihto on supistunut 37,8 % vuodessa viimeisten 16 vuoden aikana 10,00 EUR:een. Quantum Genomicsn nettomarginaali −88 926 030,0 % on laskenut verrattuna −887,0 %:iin muutama vuosi sitten.
Quantum Genomics osakekurssi
Quantum Genomics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Quantum Genomics -osakkeesta
Quantum Genomics SA is primarily present in multiple countries and regions. The company has a global presence with a significant focus on key markets such as the United States, Europe, and Asia. Quantum Genomics SA operates in various countries within these regions, including France, the United Kingdom, Germany, Belgium, Switzerland, China, Japan, and South Korea. With its expanding international footprint, Quantum Genomics SA aims to reach a wide range of markets and capitalize on the global potential for its innovative pharmaceutical solutions.
The business model of Quantum Genomics SA is focused on developing treatments for cardiovascular diseases and hypertension. By leveraging its unique expertise in the field of brain aminopeptidases and its understanding of their role in cardiovascular diseases, Quantum Genomics aims to create innovative and effective therapies. The company's approach involves developing drugs that target specific brain aminopeptidases, inhibiting their activity and ultimately reducing blood pressure. Through its research and development efforts, Quantum Genomics aims to provide patients with improved treatment options and contribute to the advancement of cardiovascular medicine.
Quantum Genomics SA is primarily active in the pharmaceutical industry.
The main competitors of Quantum Genomics SA in the market include pharmaceutical companies like Novartis AG, Pfizer Inc., and AstraZeneca PLC. These companies actively participate in the development and commercialization of cardiovascular and central nervous system (CNS) medicines, similar to Quantum Genomics SA. With its innovative approach in developing drugs targeting hypertension and heart failure, Quantum Genomics SA competes with established pharmaceutical players to expand its market presence. By leveraging its distinctive technology and scientific expertise, Quantum Genomics SA aims to gain a competitive edge and capture a significant market share in the cardiovascular and CNS therapeutic areas.
Quantum Genomics SA is a leading biopharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. Founded in 2005, Quantum Genomics has made significant strides in the field of hypertension and heart failure research. With a focus on pioneering new therapeutic approaches, the company has developed QGC001, a first-in-class medication targeting brain aminopeptidase A (APA). By leveraging its expertise in molecular and cellular pharmacology, Quantum Genomics aims to revolutionize cardiovascular treatments and improve patient outcomes. With a dedicated team and a strong pipeline, Quantum Genomics SA continues to make advancements in its pursuit of breakthrough solutions for cardiovascular health.
Quantum Genomics SA, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully completed Phase IIb clinical trials for its flagship drug, Firibastat, demonstrating its effectiveness in treating hypertension and heart failure. Quantum Genomics also secured strategic partnerships with renowned pharmaceutical companies, accelerating the drug's development and expanding its market reach. Furthermore, the company obtained regulatory approvals in Europe and the United States, paving the way for commercialization. Quantum Genomics SA's dedication to innovation and clinical excellence has positioned it as a key player in the field of cardiovascular diseases, with promising prospects for future growth and success.
Quantum Genomics SA represents values of innovation, dedication, and excellence in the field of cardiovascular diseases. The company's corporate philosophy revolves around their commitment to developing breakthrough therapies for patients suffering from high blood pressure and heart failure. Quantum Genomics SA aims to provide effective solutions through their cutting-edge research and pharmaceutical advancements. With a focus on addressing unmet medical needs, they strive to improve the quality of life for individuals worldwide. By combining scientific expertise and a patient-centric approach, Quantum Genomics SA is dedicated to making a significant impact on cardiovascular healthcare.
7 analyytikkoa arvioi tällä hetkellä Quantum Genomics-osaketta: 0 suosittaa ostoa, 2 pitoa ja 5 myyntiä. Vuodelle 2026 analyytikot odottavat Quantum Genomics-yhtiöltä 159,00 M EUR liikevaihtoa ja 5,96 EUR osakekohtaista tulosta.
Quantum Genomics-osake (ALQGC.PA) on listattuna 6 pörssissä, muun muassa: London (0D1J.L), Frankfurt (2QG.F), München (2QG.MU), Paris (ALQGC.PA).
Quantum Genomics SA is a French biotechnology company specializing in the development of new therapies for hypertension and heart failure. The company uses its unique technology platform to develop drugs that interact with the brain in a unique way. Its business model is based on the invention, development, production, and marketing of innovative, novel, and patented medications for the treatment of cardiometabolic diseases. The company focuses on developing its capabilities in research, development, and commercial activities. It aims to sell its innovative technologies and products worldwide through collaboration with local and international leading research centers in cardiometabolic research. With a team of experienced researchers and experts in the pharmaceutical industry, Quantum Genomics is able to bring its products to market quickly and efficiently. The company continuously invests in research and development to improve its technologies and develop new products. It aims to maintain its competitive advantage through the protection of its intellectual property rights and collaboration with other pharmaceutical companies and research organizations. One of Quantum Genomics’ core areas is the research and development of new therapies for hypertension and heart failure. The company has conducted extensive clinical research and developed several drug candidates that interact with the brain in innovative ways, promoting better blood pressure and cardiovascular health. The company has already achieved a significant milestone by successfully gaining approval for its development candidates for clinical trials. Quantum Genomics also has partnerships with other pharmaceutical companies to maximize the potential of its technologies and increase its presence in the market. Through strategic partnerships and licensing agreements, Quantum Genomics aims to market its technology platform worldwide. In addition to its work in cardiometabolic research, Quantum Genomics also has an extensive pipeline of drug candidates for other diseases, such as chronic pain and other psychiatric disorders. The company has already achieved important milestones and established its innovative products in the market. It has strong growth potential and is on a positive path to becoming a key player in the pharmaceutical and biotechnology industry. Overall, Quantum Genomics SA's business model is focused on the development and marketing of innovative therapies for cardiometabolic diseases. The company aims to protect its innovation capabilities and intellectual property rights to strengthen its position in the market and achieve a leadership position in the industry. Quantum Genomics is committed to increasing its presence both in France and internationally and developing partnerships with other pharmaceutical companies to market its technology platform worldwide.
odotettu liikevaihto Quantum Genomics on 159,00 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Quantum Genomics on 415,47 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Quantum Genomics:n hinta-voitto-suhde (P/E) on tällä hetkellä 0,01. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Quantum Genomics-osakkeen arvostusta.
Quantum Genomics:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,03. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Quantum Genomics-osakkeen arvostuskennuslukuna.
Quantum Genomics:n Eulpool-laatuscore on 2/10.
Quantum Genomics:n ISIN on FR0011648971. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Quantum Genomics:n WKN on A1XAEB. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Quantum Genomics:n ticker on ALQGC.PA. Tämä pörssinoteeraus käytetään Quantum Genomics-osakkeiden kauppaan pörssissä.
Quantum Genomics osake
Quantum Genomics vertaisryhmä
Quantum Genomics Ticker
Quantum Genomics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Quantum Genomics:sta
Meidän osakeanalyysimme Quantum Genomics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Quantum Genomics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: